Petros Pharmaceuticals, Inc. is focused on the self-care market by providing expanded access to key prescription pharmaceuticals such as OTC treatment options. The Company is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions.
Código de la empresaPTPI
Nombre de la empresaPetros Pharmaceuticals Inc
Fecha de salida a bolsaDec 02, 2020
Fundada en2020
Director ejecutivo- -
Número de empleados18
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 02
Dirección1185 Avenue Of The Americas, 3Rd Floor
CiudadNEW YORK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal10036
Teléfono19732420005
Sitio Webhttps://www.petrospharma.com/
Código de la empresaPTPI
Fecha de salida a bolsaDec 02, 2020
Fundada en2020
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos